The importance of maintaining effective therapy in multiple sclerosis

Journal of Neurology

Volumn 252, Issue SUPPL. 3, 2005, Pages

  Durelli, Luca ^a,b   Clerico, Marinella ^b  

^a SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

INCOMIN; Interferon beta 1a; Interferon beta 1b; Multiple sclerosis; OPTIMS

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS;

EID: 25144521752     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-2016-0     Document Type: Conference Paper

References (20)

1. Barbero P, Pipieri A, Verdun E, Bergui M, Isoardo G, Bosio A (2002) Is it possible to reduce the dose of interferon (IFN) beta in MS patients with a prolonged MRI-confirmed absence of disease activity? Neurology 58:A493
2. Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L (2004) High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study. J Neurol Sci 222:13-19
3. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59:1507-1517
4. Durelli L, Barbero P, Verdun E, Clerico M, Pipieri A, Bergamasco B, Bergui M (2003) Reducing interferon beta dose in chronically-treated MS patients may have long-term deleterious effects on disease activity. AAN, Hawaii, 2003
5. Durelli L, Oggero A, Verdun E, Barbero P, Pipieri A, Isoardo G, Ricci A, Clerico M, Bradac G, Bergamasco B, Bergui M (2001) Interferon-beta dose and efficacy: the OPTIMS study. Neurol Sci 22:201-203
6. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453-1460
7. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169-178
8. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double- blind, placebo-controlled trial. Neurology 43:655-661
9. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, III, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294
10. Knobler RL, Greenstein JI, Johnson KP, Lublin FD, Panitch HS, Conway K, Grant-Gorsen SV, Muldoon J, Marcus SG, Wallenberg JC, et al. (1993) Systemic recombinant human interferon-beta treatment of relapsing- remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 13:333-340
11. Once Weekly Interferon for MS Study Group (1999) Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 53:679-686
12. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59:1496-1506
13. Paty DW, Li DK (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43:662-667
14. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
15. Rothuizen LE, Buclin T, Spertini F, Trinchard I, Munafo A, Buchwalder PA, Ythier A, Biollaz J (1999) Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 99:131-141
16. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer M, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Whitham RH (1998) Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 43:79-87
17. Sturzebecher S, Maibauer R, Heuner A, Beckmann K, Aufdembrinke B (1999) Pharmacodynamic comparison of single doses of IFN-beta-1a and IFN-beta-1b in healthy volunteers. J Interferon Cytokine Res 19:1257-1264
18. Walther EU, Hohlfeld R (1999) Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 53:1622-1627
19. Williams GJ, Witt PL (1998) Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron® and AVONEX®. J Interferon Cytokine Res 18:967-975
20. Zhao GJ, Koopmans RA, Li DK, Bedell L, Paty DW (2000) Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group. Neurology 54:200-206